Asset profile
CMS121
Small molecule
Evidence outlook · lead readout
NCT05318040 · Alzheimer Disease
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT05318040: The core parts of the study randomly assigned healthy volunteers to CMS121 or a matching placebo with participants, care providers, and investigators blinded, which are the hallmarks of a well-controlled study. However, it tested only safety and drug levels in healthy volunteers, not any Alzheimer's-related benefit, and results have not been posted.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.